Compare IQIYI Inc - ADR (IQ) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IQIYI Inc - ADR vs Neurocrine Biosciences Inc — how do they compare? IQIYI Inc - ADR trades at $1.02 (market cap $974.67M), while Neurocrine Biosciences Inc trades at $141.09 (market cap $14.36B). The key difference: Neurocrine Biosciences Inc is far larger — about 14.7× IQIYI Inc - ADR's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, IQIYI Inc - ADR nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold IQIYI Inc - ADR for 55 Days and Neurocrine Biosciences Inc for 23 Days on average.
| IQ | NBIX | |
|---|---|---|
Market Cap | $974.67M | $14.36B |
Volume | 4,964,108 | 1,237,180 |
Sector | Media | Health |
52-Week High | $2.35 | $185.50 |
52-Week Low | $0.86 | $123.10 |
Typical Hold Time | 55 Days | 23 Days |
Enterprise Value | $2.47B | $14.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IQ trades at $1.015, up 0.5% on the day, with a neutral technical signal and bearish moving averages. The company reported a net loss of $206.31 million in 2025 despite beating EPS estimates in recent quarters. Revenue declined to $27.29 billion, and negative profit margins persist. Analyst sentiment is mixed with a 50% buy rating. Recent news highlights iQIYI's focus on AI-driven content, including new titles and revenue-sharing successes.
The outlook is cautious due to revenue contraction and recurring losses, though AI initiatives offer growth potential. Key risks include competitive pressures in streaming and reliance on Chinese market dynamics. Institutional ownership trends and earnings performance in upcoming quarters will be critical for stock direction.
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, with a bearish technical signal but strong fundamentals including a 20.91% net income margin and consistent earnings beats. Recent news highlights pipeline advancements in Prader-Willi syndrome and executive appointments, while analyst consensus remains strongly bullish with a $204.18 price target.
The outlook is positive based on robust profitability and growth initiatives, though risks include execution of pipeline diversification and potential pricing pressure on key drug Ingrezza. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharma company with a deep pipeline, balanced by near-term technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About IQIYI Inc - ADR
iQIYI Inc is an online entertainment service provider in China. It is primarily engaged in providing a variety of services encompassing internet video, live broadcasting, online games, online literature, animations, e-commerce, and social media platform. The company produces original video content and distributes appealing professionally produced content, partner-generated content, and user-generated content. It also offers a diverse collection of internet video content that appeals to users from broad demographics. The company's revenue is generated from membership services and online advertising services. The company earns most of its revenue from China.
Read more on IQ →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
